Fresenius SE & Co. KGaA
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Sen
- Full Time Employees
- 175,202
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Else-Kroener-Strasse 1 Bad Homburg vor der Höhe Germany 61352
- IPO Date
- May 15, 2012
- Website
- fresenius.com
- Similar Companies
- Business
- Fresenius SE & Co. KGaA is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany, founded in 1912. The company operates primarily through its core business segments: Fresenius Kabi, which specializes in biopharmaceuticals, clinical nutrition, MedTech products including infusion systems, intravenously administered generic drugs, and IV fluids; Fresenius Helios, the leading private hospital operator in Europe with extensive inpatient and outpatient services primarily in Germany and Spain; and Fresenius Medical Care, a publicly traded company in which Fresenius holds a significant stake, focusing on dialysis products and services for patients with chronic kidney failure globally. Fresenius Kabi supports critically and chronically ill patients with therapeutic products such as biologic drugs, clinical nutrition including enteral and parenteral nutrition, and infusion therapy products. Fresenius Helios operates more than 110 hospitals and treats over 4 million patients annually. Fresenius Medical Care provides dialysis machines, dialyzers, renal pharmaceuticals, and related medical devices, holding a strong market position especially in the U.S. and Europe. Recent major company changes include the continued strategic transformation under the #FutureFresenius program which focuses on three therapy platforms: (bio)pharma including clinical nutrition, MedTech, and care provision. In 2024-2025, Fresenius has completed significant portfolio optimization including the sale of the Eugin Group, strengthened its biopharma business through partnerships and integration with mAbxience, and launched several new innovative products such as the pediatric parenteral nutrition 3-Chamber-Bag PediSmof. The company has expanded its digital health and advanced therapy investments and is pursuing growth through outpatient sector expansions by linking medical care centers more closely to hospitals. Fresenius also secured a €400 million loan from the European Investment Bank to support R&D innovation and capacity expansion. Financially, Fresenius reported strong organic growth with Q3 2025 revenues at €5.477 billion and raised EBIT growth guidance, driven by consistent performance in Fresenius Kabi and Helios despite challenging macroeconomic conditions. Fresenius operates in over 60 countries with over 50 production sites worldwide, targeting healthcare providers, hospitals, and chronically ill patients. The company is positioned to leverage trends like aging populations and healthcare expansion globally. Its latest strategic focus involves simplifying the group structure, optimizing financial management, and creating sustainable value through innovative, accessible, and affordable healthcare products and services. This description integrates the company's detailed product offerings, geographic reach, strategic initiatives, and recent operational and financial developments reflecting its position as a leading global healthcare provider.
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Fresenius SE & Co. KGaA (FSNUY) Q1 2026 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fresenius SE & Co. (OTCMKTS:FSNUY) vs. U.S. Physical Therapy (NYSE:USPH) Head to Head Review
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
Financial Review: Fresenius SE & Co. (OTCMKTS:FSNUY) vs. DaVita (NYSE:DVA)
Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript
Fresenius: Healthy Portfolio Add
Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript
Fresenius: Turnaround For Company, Stock Price
Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript
Fresenius: The Signs Of A Significant Turnaround Are Getting Clearer And Clearer
Fresenius SE & Co. KGaA (FSNUF) Q3 2024 Earnings Call Transcript
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Is Fresenius SE & Co. (FSNUY) Stock Undervalued Right Now?
Fresenius: Showing Signs Of Recovery, We Have Dawn
Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript